TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01990066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Exercise
Description: Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
Study: NCT02353429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Description: Patients will receive 60 mg daily and then 180 daily in case of progression
Study: NCT02544100

Intervention type: OTHER
Intervention: Database Entry/Biospecimen Collection
Description: blood, urine, CFS samples and medical data collected
Study: NCT03997331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CRx Health
Description: CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRx Health
Description: CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronicare
Description: Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
Study: NCT00196222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF-ablation
Description: RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryo ablation
Description: Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
Study: NCT03627182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study).
Study: NCT03888716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333
Description: 25 and 100 mg KL1333 encapsulated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 25 and 100 mg placebo encapsulated tablets
Study: NCT03793595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seated Battle Ropes Protocol
Description: Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seated Upper Extremity Arm Bike
Description: A modified Young Men's Christian Association (YMCA) cycle test will be performed.
Study: NCT04202354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HSD Injection
Description: single or multiple doses of ARO-HSD by subcutaneous (sc) injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline (0.9% NaCl)
Description: calculated volume to match active treatment, by sc injection
Study: NCT01089049

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FemMED Breast Health Formula
Description: Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FemMED Breast Health Formula
Description: Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
Study: NCT00591253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT01160198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous ascorbate
Description: 100 mg elemental iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous bisglycinate chelate 1 OD
Description: 60 mg elemental iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous bisglycinate chelate 2 OD
Description: 120 mg elemental iron
Study: NCT03341598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: Restorative procedure to treat tooth structure loss.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R
Description: Restorative procedure to treat tooth structure loss.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MC
Description: Xenogenous graft placed in the surgical site.
Study: NCT04039165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-MI Intervention
Description: The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
Study: NCT04363736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociliuzumab
Description: Participants will receive IV TCZ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tociliuzumab
Description: Participants will receive IV TCZ.
Study: NCT00142454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein
Description: NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
Study: NCT02289391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia induction
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia maintenance
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.
Study: NCT00505128

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic sphincterotomy
Description: procedure
Study: NCT03008629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Podofix nail brace
Description: Podofix nail brace

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combiped nail brace
Description: Combiped nail brace

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Podofix and then Combiped nail brace
Description: Podofix and then Combiped nail brace
Study: NCT03351413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIVE-LiFE to Prevent Falls Among Older Fallers
Description: LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)
Study: NCT00251771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed venous thrombolysis
Description: catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
Study: NCT01308983

Intervention type: DRUG
Group type: OTHER
Intervention: Amiloride
Description: Amiloride 10 mg orally once a day for 16 weeks
Study: NCT00003299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT04567199

Intervention type: OTHER
Intervention: Observational, retrospective
Description: retrospective analysis of observed results, for both study groups.

Intervention type: OTHER
Intervention: Observational, retrospective
Description: retrospective analysis of observed results, for both study groups.
Study: NCT02289391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia maintenance
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assisted anesthesia
Description: Intervention 'Assisted anesthesia' has been included in Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assisted anesthesia
Description: Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
Study: NCT03013010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-Gimeracil-Oteracil Potassium
Description: The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-Gimeracil-Oteracil Potassium
Description: The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric resection
Description: A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric resection
Description: A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study: NCT02220972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04304833

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider-Based Care Model Arm
Description: The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Model Arm
Description: The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
Study: NCT03776136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Administered orally once a day during each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W.
Study: NCT00655980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and folic acid
Description: 1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous oxide and placebo

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Study: NCT01953796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene
Description: For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene
Description: For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
Study: NCT02353923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OcuStem Supplementation
Description: 2800 mg daily dosage of OcuStem, 2 capsules BID.
Study: NCT01146236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Description: Orthopedic surgical wounds closed with sutures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Orthopedic surgical wounds closed with metallic staples
Study: NCT02459574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVATAR-AF ablation
Description: Experimental ablation protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmic therapy
Description: Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AF ablation
Description: Conventional ablation procedure
Study: NCT02911779

Intervention type: PROCEDURE
Group type: OTHER
Intervention: change of medilateral angle line during crowning of the head
Description: change of medilateral angle line during crowning of the head
Study: NCT00466856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 resin microspheres
Description: radiation
Study: NCT03156517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Study: NCT01271933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: controlled release tablet; 165-495 mg/day; given once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet; given once daily
Study: NCT03690869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab (monotherapy)
Description: To be administered intravenously as monotherapy in Phase 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab (maintenance)
Description: To be administered intravenously in combination with radiation and then used as maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab (maintenance)
Description: To be administered intravenously in combination with radiation and then used as maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab (maintenance)
Description: To be administered intravenously in combination with radiation and then used as maintenance therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional or hypofractionated
Description: Combined with cemiplimab IV administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional or hypofractionated
Description: Combined with cemiplimab IV administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Combined with cemiplimab IV administration
Study: NCT01642771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fu/epirubicin/CTX following Docetaxel
Description: Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/capecitabine followed by XEC
Description: Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
Study: NCT03023878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's Choice Chemotherapy
Description: During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).